Evidence map›Paper›PMID 36890182›Full record

ArticleScientific reports2023

Prognostic significance of pre- and post-treatment hematological biomarkers in patients with head and neck cancer treated with chemoradiotherapy.

Yoh-Ichiro Iwasa, Moeka Shimizu, Kazuki Matsuura, Kentaro Hori, Ken Hiramatsu, Kenjiro Sugiyama, Yoh Yokota, Tomohiro Kitano, Ryosuke Kitoh, Yutaka Takumi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yoh-Ichiro IwasaDepartment of Otorhinolaryngology-Head and Neck Surgery, Shinshu University School of Medicine, 3-1-1, Asahi, Matsumoto City, 390-8621, Japan. iwasa@shinshu-u.ac.jp.
Moeka ShimizuShinshu University School of Medicine, 3-1-1, Asahi, Matsumoto City, 390-8621, Japan.
Kazuki MatsuuraDepartment of Otorhinolaryngology-Head and Neck Surgery, Shinshu University School of Medicine, 3-1-1, Asahi, Matsumoto City, 390-8621, Japan.
Kentaro HoriDepartment of Otorhinolaryngology-Head and Neck Surgery, Shinshu University School of Medicine, 3-1-1, Asahi, Matsumoto City, 390-8621, Japan.
Ken HiramatsuDepartment of Otorhinolaryngology-Head and Neck Surgery, Shinshu University School of Medicine, 3-1-1, Asahi, Matsumoto City, 390-8621, Japan.
Kenjiro SugiyamaDepartment of Otorhinolaryngology-Head and Neck Surgery, Shinshu University School of Medicine, 3-1-1, Asahi, Matsumoto City, 390-8621, Japan.
Yoh YokotaDepartment of Otorhinolaryngology-Head and Neck Surgery, Shinshu University School of Medicine, 3-1-1, Asahi, Matsumoto City, 390-8621, Japan.
Tomohiro KitanoDepartment of Otorhinolaryngology-Head and Neck Surgery, Shinshu University School of Medicine, 3-1-1, Asahi, Matsumoto City, 390-8621, Japan.
Ryosuke KitohDepartment of Otorhinolaryngology-Head and Neck Surgery, Shinshu University School of Medicine, 3-1-1, Asahi, Matsumoto City, 390-8621, Japan.
Yutaka TakumiDepartment of Otorhinolaryngology-Head and Neck Surgery, Shinshu University School of Medicine, 3-1-1, Asahi, Matsumoto City, 390-8621, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to investigate the prognostic value of hematological biomarkers measured before and after treatment in patients with head and neck cancer (HNC). This study reviewed 124 patients with HNC who received chemoradiotherapy. Hematological biomarkers assessed before and after treatment were investigated. The pretreatment C-reactive protein/albumin ratio (pre-CAR) and post-treatment prognostic nutritional index (post-PNI) showed the highest area under the curve with cutoff values of 0.0945 and 34.9, respectively. Patients in the high pre-CAR group showed significantly worse prognosis than those in the low pre-CAR group with respect to the progression-free survival (PFS) (3-year PFS: 44.8% vs. 76.8%, p < 0.001) and overall survival (OS) (3-year OS: 65.8% vs. 94.0%, p < 0.001). Patients in the low post-PNI group showed significantly worse prognosis than those in the high post-PNI group with respect to the PFS (3-year PFS: 58.6% vs. 77.4%, p = 0.013) and OS (3-year OS: 75.2% vs. 96.9%, p = 0.019). Multivariate analysis revealed that advanced N stage (p = 0.008), high pre-CAR (p = 0.024), and low post-PNI (p = 0.034) were significantly associated with poorer OS. We suggest that the evaluation of hematological markers before and after treatment is useful for predicting disease progression and survival.

Indexed as

Head and Neck NeoplasmsNutrition AssessmentBiomarkersChemoradiotherapyHumansPrognosisRetrospective StudiesBiomarkers

Identifiers

PMID36890182
PMCPMC9995483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.